• Acelrx Pharmaceuticals Inc., of Redwood City, Calif., was issued U.S. Patent No. 8,499,966, “Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms”; No. 8,535,714, “Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain”; and No. 8,548,623, “Storage and dispensing devices for administration of oral transmucosal dosage forms.”
• Biolinerx Ltd., of Jerusalem, was issued a U.S. Patent notice of allowance for BL-5010, its product used in the nonsurgical removal of skin lesions.
• Cellular Dynamics International Inc., of Madison, Wis., was issued U.S. Patent No. 8,546,140, “Methods for the Production of iPS Cells Using Non-Viral Approach.” The patent is related to reprogramming adult tissue cells, such as blood or skin, into induced pluripotent stem cells by inserting episomal vectors.
• Discovery Laboratories Inc., of Warrington, Pa., was issued a U.S. Patent notice of allowance for No. 12/285,312, “Capillary System With Fluidic Element.” The patent is related to the company’s capillary aerosol generator technology for its Aerosurf program.
• Geovax Labs Inc., of Atlanta, was issued a U.S. Patent notice of allowance No. 10/336,566, “Composition and Methods for Generating an Immune Response,” which was licensed from Emory University and the U.S. Government. The patent is related to the company’s DNA/MVA vaccine for HIV/AIDS.
• Medicinova Inc., of San Diego, was issued a U.S. Patent notice of allowance for the company’s MN-029 (denibulin) di-hydrochloride, which covers the compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors.
• Oncomed Pharmaceuticals Inc., of Redwood City, Calif., was issued U.S. Patent No. 8,551,715, for its MabTrap antibody display technology.